Reporter virus particles (RVPs) package the capsid-preMembrane-envelope (C-prM-E) gene construct of Dengue virus (DENV) (GenBank: MK506263.1, Serotype 2 strain) and a Renilla luciferase reporter.

• Anti-Dengue virus neutralizing antibody screening at high throughput
• Anti-Dengue virus drug screening at high throughput
• Dengue virus vaccine efficacy evaluation at high throughput
• Dengue virus pseudovirus transduction of target cells for viral entry, receptor recognition, cellular tropism and functional studies, such as ADCC or ADE analysis

Description: Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. See our titration result showing that the starting 2-fold diluted pseudovirus generates signal 1,000-fold higher than uninfected control (cell alone as background in blue). We also evaluated the neutralizing activity of monoclonal antibody (mAb) - domain Ⅲ specific RV25.

Size: 200 μl with recommended 10-fold dilution. We recommend to use it at a dilution fold where the signal of RVP infection is >100-fold higher than uninfected control (cell alone as background). Can be used for 20 reactions (100 μl diluted virus) or 50 reactions if using reduced amount of RVP (40 μl diluted virus).

Use protocol: Incubate 100 μl diluted pseudovirus with 100 μl of your sample in each well of 96-well plate with at least one duplicate for 30 to 60 min at 37 °C. Then add 100 μl target cells (Huh-7, Vero or others expressing receptor). Read luciferase signal next day. For protocol using reduced amount, incubate 40 μl diluted virus with 10 μl your sample in each well of 96-well plate for 30 to 60 min at 37 °C. Then add 25 μl target cells. Add 150 μl fresh media next day and read signal on Day 3. To be noted for neutralizing titer (such as EC50) calculation, more duplication leads to more accurate reading.